Nurix Therapeutics, Inc.
NRIX
$15.60
-$0.13-0.83%
NASDAQ
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 9.49% | -98.83% | 22.87% | 3.75% | -19.60% |
| Total Depreciation and Amortization | -19.38% | -1.90% | 23.47% | 37.46% | -27.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.52% | -1.42% | 48.77% | 2.36% | -5.40% |
| Change in Net Operating Assets | -109.42% | 150.68% | -131.51% | -3,224.50% | 116.62% |
| Cash from Operations | -18.21% | 9.14% | -3.40% | -25.30% | -15.59% |
| Capital Expenditure | -89.27% | -1.35% | 23.24% | -65.56% | 10.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.70% | -28.30% | 155.61% | 120.92% | -630.37% |
| Cash from Investing | -99.31% | -29.40% | 180.03% | 118.13% | -559.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20,333.59% | 19,150.00% | -99.59% | -99.27% | 338.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 20,333.59% | 19,150.00% | -99.59% | -99.27% | 338.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,028.27% | -168.97% | 124.48% | -411.16% | 161.72% |